Colon cancer in a patient with a mosaic monoallelic germline pathogenic NF1 gene variant

Abstract

Pathogenic variants in the tumor suppressor gene NF1 cause neurofibromatosis type 1 (NF1), one of the most common hereditary cancer predisposition syndromes. Pathogenic NF1 variants have been associated with an increased risk of several cancers; however, the relationship between NF1 variation and colon cancer remains underreported. We report a 41-year-old woman with a mosaic monoallelic germline pathogenic NF1 variant, NM_000267.3:c.1756_1759del (p.Thr586Valfs*18), previously detected on germline multigene panel testing in saliva at a variant allele frequency of approximately 35%. She later presented with fatigue, dyspnea on exertion, and iron-deficiency anemia. Computed tomography, colonoscopy, biopsy, mismatch repair immunohistochemistry, surgical pathology, and tumor next-generation sequencing led to the diagnosis of right-sided colon adenocarcinoma that was mismatch repair deficient (dMMR) and microsatellite instability-high (MSI-H). She underwent right hemicolectomy, recovered postoperatively, and entered standard surveillance; at the time of manuscript development, she was also receiving systemic therapy. This case highlights the co-occurrence of an NF1 variant and dMMR colorectal cancer and underscores the need for further studies to determine whether this represents a coincidental finding or a biologically meaningful association.

Keywords

NF1 / colon / cancer / frameshift / germline

References

[1] Safonov A, Nomakuchi TT, Chao E, Horton C, Dolinsky JS, Yussuf A, et al.A genotype-first approach identifies high incidence of NF1 pathogenic variants with distinct disease associations. Nat Commun. 2025; 16:3121.

[2] Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, et al.Type 1 Neurofibromatosis Gene: Identification of a Large Transcript Disrupted in Three NF1 Patients. Science. 1990; 249:181-6.

[3] Lee TJ, Chopra M, Kim RH, Parkin PC, Barnett-Tapia C. Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet J Rare Dis. 2023; 18:292.

[4] Yap YS, McPherson JR, Ong CK, Rozen SG, Teh BT, Lee AS, et al.The NF1 gene revisited—from bench to bedside. Oncotarget. 2014; 5:5873-92.

[5] Dasgupta B, Dugan LL, Gutmann DH. The Neurofibromatosis 1 Gene Product Neurofibromin Regulates Pituitary Adenylate Cyclase-Activating Polypeptide-Mediated Signaling in Astrocytes. J Neurosci. 2003; 23:8949-54.

[6] Koczkowska M, Callens T, Chen Y, Gomes A, Hicks AD, Sharp A, et al.Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype–phenotype study in neurofibromatosis type 1. Hum Mutat. 2020; 41:299-315.

[7] Mantalovas S, Karakousis VA, Sevva C, Roulia P, Savvakis S, Anthimidis G, et al.Multifocal Gastrointestinal Stromal Tumors (GISTs) of the Small Intestine in Patients with Neurofibromatosis Type 1 (NF-1): Meta-Analysis and Systematic Review of the Literature. Cancers. 2025; 17:1934.

[8] Ibrahimi A, Lachkar S, Boualaoui I, El Sayegh H, Nouini Y. Gastrointestinal stromal tumor in patient with neurofibromatosis type 1: A case report. Int J Surg Case Rep. 2025; 129:111166.

[9] Cerrah E, Çomunoğlu C. Multiple Gastrointestinal Stromal Tumors, Malignant Peripheral Nerve Sheath Tumor and Atypical Neurofibromatous Neoplasm With Uncertain Biologic Potential Developing in A Single Patient With Neurofibromatosis Type 1 Syndrome. Int J Surg Pathol. 2024; 32:1415-21.

[10] Deshpande A, Munoz J, Dabak V, Hanbali A, Kurzrock R. Images in Immunotherapy and Precision Oncology: A Case Report of Neurofibromatosis-1. J Immunother Precis Oncol. 2024; 7:122-5.

[11] Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al.Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2022; 72:338-44.

[12] Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: Cancer J Clin. 2024; 74:12-49.

[13] Eng C, Yoshino T, Ruiz-García E, Mostafa N, Cann CG, O'Brian B, et al.Colorectal cancer. Lancet. 2024; 404:294-310.

[14] Storandt MH, Sinicrope FA. Deficient mismatch repair/microsatellite instability-high colorectal cancer: current treatment paradigms, limitations and future perspectives. BMJ Oncol. 2026; 5:e000980.

[15] Taieb J, Svrcek M, Cohen R, Basile D, Tougeron D, Phelip JM. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment. Eur J Cancer. 2022; 175:136-57.

[16] Lou H, Zhai C, Gong L, Pan H, Pan H, Zhang Y, et al.NF1 germline mutation in a Chinese family with colon cancer. J Int Med Res. 2020; 48:300060519896435.

[17] Oh SH, Lee JH, Namgung H. A Case of Rectal Cancer in a Patient with Neurofibromatosis Type 1. J Korean Soc Coloproctology. 2012; 28:170-3.

[18] Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D, et al.The CARE guidelines: consensus-based clinical case reporting guideline development. BMJ Case Rep. 2013; 2013:bcr2013201554.

[19] Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, et al.Sherloc: a comprehensive refinement of the ACMG–AMP variant classification criteria. Genet Med. 2017; 19:1105-17.

[20] Eroglu S, Birsenogul I, Bowen AP, Doyle JF, Pupkin SE, Villar J, et al.Lynch Syndrome in Focus: A Multidisciplinary Review of Cancer Risk, Clinical Management, and Special Populations. Cancers. 2025; 17:3981.

[21] Gómez-Molina R, Martínez R, Suárez M, Peña-Cabia A, Calderón MC, Mateo J. Lynch syndrome and colorectal cancer: A review of current perspectives in molecular genetics and clinical strategies. Oncol Res. 2025; 33:1531-45.

[22] Oliver TRW, Lawson ARJ, Lee-Six H, Tollit A, Jung H, Hooks Y, et al.Cancer-independent somatic mutation of the wild-type NF1 allele in normal tissues in neurofibromatosis type 1. Nat Genet. 2025; 57:515-21.

[23] Nguyen LH, Goel A, Chung DC. Pathways of Colorectal Carcinogenesis. Gastroenterology. 2020; 158:291-302.

[24] Chan WY, Pires da Silva I, Long GV, Rizos H. Targeting MEK in cancer and beyond: mechanistic insights and therapeutic opportunities. Lancet. 2026; 407:1639-56.

[25] Suppiah S, Mansouri S, Bril V, Zadeh G. Special issue: a contemporary landscape of the clinical and biological research in neurofibromatosis type 1. Neurooncol Adv. 2020; 2:i8-12.

[26] Anastasaki C, Woo AS, Messiaen LM, Gutmann DH. Elucidating the impact of neurofibromatosis-1 germline mutations on neurofibromin function and dopamine-based learning. Hum Mol Genet. 2015; 24:3518-28.

[27] Bhamidipati D, Subbiah V. Tumor-agnostic drug development in dMMR/MSI-H solid tumors. Trends Cancer. 2023; 9:828-839.

[28] Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, et al.Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2006; 44:81-8.

[29] Carton C, Evans DG, Blanco I, Friedrich RE, Ferner RE, Farschtschi S, et al.ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. eClinicalMedicine. 2023; 56:101818.

[30] Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, et al.Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2024; 22:e22.

[31] Saqi IK, Nielsen AT, Madsen MT, Gögenur I, Orhan A, Justesen TF. Tumor characteristics impact prognosis in deficient mismatch repair/microsatellite instability-high localized colorectal cancer—a systematic review and meta-analysis. JNCI Cancer Spectr. 2025; 10:e10.

[32] Kim JH, Kang GH. Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer. World J Gastroenterol. 2014; 20:4230-43.